Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146217 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection
A Phase 2 study, sponsored by Saptalis Pharmaceuticals.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07146217: Clinical Trial Phase 2 study, sponsored by Saptalis Pharmaceuticals.
NCT07146217 is a Phase 2 study that has not yet begun recruiting, run by Saptalis Pharmaceuticals. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07146217, a Phase 2 study, has not yet begun recruiting, sponsored by Saptalis Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection
Primary Outcome
Pharmacokinetic profile of metronidazole and hydroxy-metronidazole (primary metabolite) measured by Cmax
Interventions
- DRUG Likmez® (metronidazole) Oral Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What is known before NCT07146217 opens enrollment
NCT07146217 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Likmez® (metronidazole) Oral Suspension is the first listed.
NCT07146217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07146217 about?
NCT07146217 is a clinical study titled "Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection". This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection
What is the current status of trial NCT07146217?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-08. Estimated completion is 2026-10.
What interventions are being tested in trial NCT07146217?
The interventions under investigation include: Likmez® (metronidazole) Oral Suspension (DRUG).
Who is sponsoring clinical trial NCT07146217?
This trial is sponsored by Saptalis Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07146217's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia